This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pluristem Announces Scientific And Investment Conferences For April 2013

Stocks in this article: PSTI

HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled to participate in several scientific and investment conferences in April 2013. To schedule a meeting with us upon availability, contact us at

Bizportal Biomed 2013 Conference

On April 10 th in Tel-Aviv, Zami Aberman, Chairman and CEO, will participate in a panel discussion entitled "Tel-Aviv New York, Gazing to the American Market and the Exit Dream" at the Bizportal Biomed 2013 Conference.

Regenerative Medicine Investor Day

On April 17 th in New York City, Mr. Aberman will present at the Regenerative Medicine Investor Day hosted by the Alliance for Regenerative Medicine. The conference provides institutional, strategic and venture investors a unique opportunity to gain insight into the top regenerative medicine and advanced therapies companies.

Israstem, The Annual Israeli Meeting of Translational Research on Stem Cells, Cell Therapy and Regenerative Medicine in Industry and Academia

On April 22 nd – 23 rd, Dr. Ohad Karnieli, VP Development and Dr. Racheli Ofir, Intellectual Property & Senior Scientist, will chair a session entitled "Tools for Research and Development" and give a presentation entitled "A Harmonized Approach in the Regulation of PLX-PAD" respectively.

BIO-International 2013 Convention

From April 22 nd – 25 th, Mr. Aberman and Dr. William Prather, Sr. VP of Corporate Development, will participate in the BIO-International 2013 Convention in Chicago, Illinois. This popular biotechnology meeting is well attended by specialty and large pharmaceutical companies from all over the world.

19th ISCT Annual Conference

On April 24 th, Dr. Ohad Karnieli, VP Development, will give a presentation entitled "Challenges and Possible Solutions to Overcome the Gap in Critical Supply Chain Issues of New and Evolving Cutting Edge Technologies of Cell Therapy" at the Annual International Society for Cell Therapy Conference in Auckland, New Zealand.

International Advanced Course on Regenerative Medicine Manufacturing

From April 28 th - May 4 th, Lior Raviv, Team Lead Process Development, will lecture at the course on Regenerative Medicine Manufacturing in Tavira-Algarve, Portugal.

Needham Healthcare Conference

From April 30 th - May 1 st, Dr. Prather will attend the 12th Annual Needham Healthcare Conference held in New York City.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs